| [1] |
World Health Organization.Global tuberculosis report 2021[R]．Geneva：World Health Organization，2021：17.
|
| [2] |
Zhang G, Howe M, Aldrich CC, et al. Spirocyclic and bicyclic 8-Nitrobenzothiazinones for tuberculosis with improved physicochemical and pharmacokinetic properties[J]． ACS Med Chem Lett， 2019， 10(3)：348-351.DOI： 10.1021/acsmedchemlett.8b00634.
|
| [3] |
Kumar N， Srivastava R， Prakash A，et al.Virtual screening and free energy estimation for identifying mycobacterium tuberculosis flavoenzyme DprE1 inhibitors[J]． J Mol Graph Model， 2021(102)：107770.DOI： 10.1016/j.jmgm.2020.107770.
|
| [4] |
Kb S， Kumari A， Shetty D，et al.Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis[J]． J Mol Graph Model， 2020(101)：107718.DOI： 10.1016/j.jmgm.2020.107718.
|
| [5] |
Gao Y, Xie J, Tang R, et al. Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening[J]． Bioorg Chem， 2019(85)：168-178.DOI： 10.1016/j.bioorg.2018.12.018.
|
| [6] |
Whitehurst BC， Young RJ， Burley GA，et al.Identificationof 2-((2，3-dihydrobenzo[b][1，4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors[J]． Bioorg Med Chem Lett， 2020， 30(12)：127192.DOI： 10.1016/j.bmcl.2020.127192.
|
| [7] |
Zhang G， Guo S， Cui H，et al.Virtual screening of small molecular inhibitors against DprE1[J]． Molecules， 2018， 23(3)：524.DOI： 10.3390/molecules23030524.
|
| [8] |
Piton J， Vocat A， Lupien A，et al.Structure-Based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from mycobacterium tuberculosis[J]． Antimicrob Agents Chemother， 2018， 62(10)：e00681-18.DOI： 10.1128/AAC.00681-18.
|
| [9] |
Balabon O， Pitta E， Rogacki MK，et al.Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-d-ribose oxidase (DprE1) inhibitors[J]． J Med Chem， 2020， 63(10)：5367-5386.DOI： 10.1021/acs.jmedchem.0c00107.
|
| [10] |
Liu L， Kong C， Fumagalli M，et al.Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents[J]． Eur J Med Chem， 2020(208)：112773.DOI： 10.1016/j.ejmech.2020.11277.
|
| [11] |
Liu R， Lyu X， Batt SM，et al.Determinants of the inhibition of DprE1 and CYP2C9 by antitubercular thiophenes[J]． Angew Chem Int Ed Engl， 2017， 56(42)：13011-13015.DOI： 10.1002/anie.201707324.
|
| [12] |
Borthwick JA， Alemparte C， Wall I，et al.Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose oxidase inhibitors: expeditious reconstruction of suboptimal hits into a series with potent in vivo activity[J]． J Med Chem， 2020， 63(5)：2557-2576.DOI： 10.1021/acs.jmedchem.9b01561.
|
| [13] |
Imran M， A S A， Thabet HK, et al.Synthetic molecules as DprE1 inhibitors: a patent review[J]． Expert Opin Ther Pat， 2021， 31(8)：759-772.DOI： 10.1080/13543776.2021.1902990.
|
| [14] |
Mariandyshev AO, Khokhlov AL, Smerdin SV, et al. The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone(PBTZ169)[J]． TeArkh， 2020， 92(3)：61-72.DOI： 10.26442/00403660.2020.03.000621.
|
| [15] |
Dube PS， Legoabe LJ， Jordaan A，et al.Easily accessed nitroquinolones exhibiting potent and selective anti-tubercular activity[J]． Eur J Med Chem， 2021(213)：113207.DOI： 10.1016/j.ejmech.2021.113207.
|
| [16] |
Foo CS， Lechartier B， Kolly GS，et al.Characterization of DprE1-mediated benzothiazinone resistance in mycobacterium tuberculosis[J]． antimicrob agents chemother， 2016， 60(11)：6451-6459.DOI： 10.1128/AAC.01523-16.
|
| [17] |
Guo S， Fu L， Wang B，et al.In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against mycobacterium tuberculosis[J]． Biomed Pharmacother， 2020(131)：110777.DOI： 10.1016/j.biopha.2020.110777.
|
| [18] |
Makarov V， Lechartier B， Zhang M，et al.Towards a new combination therapy for tuberculosis with next generation benzothiazinones[J]． EMBO Mol Med， 2014， 6(3)：372-383.DOI： 10.1002/emmm.201303575.
|
| [19] |
Robertson GT， Ramey ME， Massoudi LM，et al.Comparative analysis of pharmacodynamics in the C3HeB/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832[J]． Antimicrob Agents Chemother， 2021， 65(11)：e0058321.DOI： 10.1128/AAC.00583-21.
|
| [20] |
Lupien A， Vocat A， Foo CS，et al.Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169)[J]． Antimicrob Agents Chemother， 2018， 62(11)：e00840-18.DOI： 10.1128/AAC.00840-18.
|
| [21] |
Spaggiari D, Desfontaine V, Cruchon S, et al.Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone(PBTZ169) and five active metabolites in human plasma[J]． PLoS One， 2019， 14(5)：e0217139.DOI： 10.1371/journal.pone.0217139.
|
| [22] |
Zhang G， Sheng L， Hegde P，et al.8-cyanobenzothiazinone analogs with potent antitubercular activity[J]． Med Chem Res， 2021， 30(2)：449-458.DOI： 10.1007/s00044-020-02676-4.
|
| [23] |
Li P， Wang B， Zhang X，et al.Identification of novel benzothiopyranone compounds against mycobacterium tuberculosis through scaffold morphing from benzothiazinones[J]． Eur J Med Chem， 2018(160)：157-170.DOI： 10.1016/j.ejmech.2018.09.042.
|
| [24] |
Grover S， Alderwick LJ， Mishra AK，et al.Benzothiazinones mediate killing of corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis[J]． J Biol Chem, 2014， 289(9)：6177-6187.DOI： 10.1074/jbc.M113.522623.
|
| [25] |
Hariguchi N, Chen X, Hayashi Y, et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor[J]． Antimicrob Agents Chemother， 2020， 64(6)：e02020-19.DOI： 10.1128/AAC.02020-19.
|
| [26] |
Wang F， Sambandan D， Halder R，et al.Identification of a small molecule with activity against drug-resistant and persistent tuberculosis[J]． Proc Natl Acad Sci U S A， 2013， 110(27)：2510-2517.DOI： 10.1073/pnas.1309171110.
|